Welcome to the UPF Digital Repository

Antidepressant drugs and COVID-19: A review of basic and clinical evidence

Show simple item record

dc.contributor.author Mas, Marta
dc.contributor.author García-Vicente, Juan Antonio
dc.contributor.author Estrada-Gelonch, Anaïs
dc.contributor.author Pérez Mañá, Clara
dc.contributor.author Papaseit Fontanet, Esther
dc.contributor.author Torrens, Marta
dc.contributor.author Farré Albaladejo, Magí
dc.date.accessioned 2023-02-02T13:29:58Z
dc.date.available 2023-02-02T13:29:58Z
dc.date.issued 2022
dc.identifier.citation Mas M, García-Vicente JA, Estrada-Gelonch A, Pérez-Mañá C, Papaseit E, Torrens M, Farré M. Antidepressant drugs and COVID-19: A review of basic and clinical evidence. J Clin Med. 2022 Jul 12;11(14):4038. DOI: 10.3390/jcm11144038
dc.identifier.issn 2077-0383
dc.identifier.uri http://hdl.handle.net/10230/55595
dc.description.abstract The COVID-19 pandemic has encouraged the repurposing of existing drugs as a shorter development strategy in order to support clinicians with this difficult therapeutic dilemma. There is evidence to support the theory that some antidepressants can reduce concentrations of different cytokines in humans and animals and, recently, the antiviral activity of some antidepressants against SARS-CoV-2 has been reported. The aims of this narrative review are to evaluate the possible role of antidepressants in the treatment of COVID-19 infection and the possible benefits and risks of patients taking antidepressants for mental disorders and COVID-19 infection. A review was performed to analyse the current literature to identify the role of antidepressant medication in the treatment of COVID-19 patients. The electronic search was completed in MEDLINE and MedRxiv/BioRxiv for published literature and in ClinicalTrials.gov for ongoing clinical trials. The results show some evidence from preclinical data and observational studies about the possible efficacy of some specific antidepressants for treating COVID-19 infection. In addition, two published phase II studies testing fluvoxamine showed positive results for clinical deterioration and hospitalization rate versus a placebo. Seven ongoing clinical trials testing fluvoxamine, fluoxetine, and tramadol (as per its anti-inflammatory and antidepressant effect) are still in the early phases. Although the available evidence is limited, the sum of the antiviral and anti-inflammatory preclinical studies and the results from several observational studies and two phase II clinical trials provide the basis for ongoing clinical trials evaluating the possible use of antidepressants for COVID-19 infection in humans. Further investigations will be needed to support the possible use of antidepressants for this application.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher MDPI
dc.relation.ispartof J Clin Med. 2022 Jul 12;11(14):4038
dc.rights © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
dc.rights.uri https://creativecommons.org/licenses/by/4.0/
dc.title Antidepressant drugs and COVID-19: A review of basic and clinical evidence
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3390/jcm11144038
dc.subject.keyword COVID-19
dc.subject.keyword SARS-CoV-2
dc.subject.keyword Antidepressant
dc.subject.keyword Antiviral
dc.subject.keyword Cytokine storm
dc.subject.keyword Fluoxetine
dc.subject.keyword Fluvoxamine
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


In collaboration with Compliant to Partaking